PARSIPPANY, N.J. and MUNICH, March 29, 2017 /PRNewswire/ -- Daiichi Sankyo Company,
Scientific research on DS-8201 and U3-1402, the two lead assets from the company's innovative Antibody Drug Conjugate (ADC) Franchise will be presented, as well as preclinical data supporting the potential role of dual EZH1/2 inhibition as a novel therapeutic strategy.
"By translating our world class medicinal chemistry and monoclonal antibody engineering science into innovative new therapies, Daiichi Sankyo's Cancer Enterprise aims to swiftly change the standard of care for many cancers," said Antoine Yver, MD, MSc, Executive Vice President and Global Head, Oncology Research and Development, Daiichi Sankyo. "We are excited to showcase the science behind our proprietary ADC technology, which we believe will more fully realize the potential of ADCs as cancer treatments."
ADC Franchise Poster Presentations Posters on two ADCs showcase the broad application of the company's proprietary payload and linker-payload technology. Preclinical research for DS-8201, a HER2-targeted ADC, will address antitumor activity in T-DM1 (ado-trastuzumab-emtansine) resistance. Additionally, the first presentations of preclinical data for U3-1402, a HER3-targeted ADC, demonstrating regression in tumors with high HER3 expression and growth inhibition in non-small cell lung cancer and breast cancer cell lines will be shared. DS-8201 and U3-1402 are both currently in phase 1 clinical development.
EZH1/2 Inhibition Poster Presentations Two posters will discuss preclinical evidence for the role of dual inhibition of the histone methyltransferases (histone-modifying enzymes) EZH1 (enhancer of zeste homolog 1) and EZH2 (enhancer of zeste homolog 2) as a novel, epigenetic treatment approach for hematologic malignancies.
About DS-8201 and U3-1402 DS-8201 and U3-1402 are antibody drug conjugates (ADC) using Daiichi Sankyo's proprietary payload and linker-payload technology designed to deliver enhanced cancer cell destruction with less systemic exposure to chemotherapy. DS-8201 is an investigational HER2-targeting ADC currently in phase 1 clinical development for HER2-positive advanced or metastatic breast cancer or gastric cancer, HER2-low-expressing breast cancer and other HER2-expressing solid cancers. The U.S. Food and Drug Administration (FDA) granted Fast Track designation to DS-8201 for the treatment of HER2-positive unresectable and/or metastatic breast cancer in patients who have progressed after prior treatment with HER2-targeted therapies including ado-trastuzumab emtansine (T-DM1). U3-1402 is an investigational and potential first-in-class HER3-targeting ADC currently in phase 1 clinical development for HER3-positive metastatic or unresectable breast cancer. It is also being evaluated in other HER3-expressing tumors such as non-small cell lung cancer. DS-8201 and U3-1402 have not been approved for any indication in any country.
About Daiichi Sankyo Cancer EnterpriseThe vision of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking in order to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by our Antibody Drug Conjugate (ADC) and Acute Myeloid Leukemia (AML) Franchises, our cancer pipeline includes more than 20 small molecules, monoclonal antibodies and ADCs stemming from our powerful research engines: our two laboratories for biologic/immuno-oncology and small molecules in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. Compounds in development include: quizartinib, an oral FLT3 inhibitor, for FLT3-ITD+ AML; DS-8201, a HER2-targeting ADC, for HER2-expressing breast or gastric cancer or other HER2-expressing solid tumors; and pexidartinib, an oral CSF-1R inhibitor, for tenosynovial giant cell tumor (TGCT), which is also being explored in a range of solid tumors in combination with the anti-PD1 immunotherapy pembrolizumab.
About Daiichi SankyoDaiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with a Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com. Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please visit: www.dsi.com.
Contact Jennifer Brennan Daiichi Sankyo, Inc. firstname.lastname@example.org +1 973 944 2393 (office) +1 201 709 9309 (mobile)
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/daiichi-sankyo-cancer-enterprise-showcases-new-data-on-multiple-compounds-at-american-association-for-cancer-research-2017-annual-meeting-300431024.html
SOURCE Daiichi Sankyo Company, Limited
Subscribe to our Free Newsletters!
A patient's struggle with Issacs' syndrome with no cure. Also known as neuromyotonia it is a rare ...
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...View All